KR101402855B1 - Ｎ-아실계 아미노산 유도체, 이의 생산방법, 약리학적조성물 및 항알러지제, 소염제 및 저지질혈제 형태에서의용도 - Google Patents

Ｎ-아실계 아미노산 유도체, 이의 생산방법, 약리학적조성물 및 항알러지제, 소염제 및 저지질혈제 형태에서의용도 Download PDF

Info

Publication number
KR101402855B1
KR101402855B1 KR1020087001210A KR20087001210A KR101402855B1 KR 101402855 B1 KR101402855 B1 KR 101402855B1 KR 1020087001210 A KR1020087001210 A KR 1020087001210A KR 20087001210 A KR20087001210 A KR 20087001210A KR 101402855 B1 KR101402855 B1 KR 101402855B1
Authority
KR
South Korea
Prior art keywords
tryptophan
glutaryl
succinyl
alpha
histidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020087001210A
Other languages
English (en)
Korean (ko)
Other versions
KR20080039872A (ko
Inventor
블라디미르 에브제니에비치 네볼씬
타트야나 알렉산드로브나 크로모바
갈리나 알렉산드로브나 젤투키나
비올레타 레오니도브나 코바레바
Original Assignee
블라디미르 에브제니에비치 네볼씬
오트크라이토에 악치오네르노에 오브스체스트보 '오테체스트베니에 레카르스트바'
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 블라디미르 에브제니에비치 네볼씬, 오트크라이토에 악치오네르노에 오브스체스트보 '오테체스트베니에 레카르스트바' filed Critical 블라디미르 에브제니에비치 네볼씬
Publication of KR20080039872A publication Critical patent/KR20080039872A/ko
Application granted granted Critical
Publication of KR101402855B1 publication Critical patent/KR101402855B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020087001210A 2005-06-15 2006-06-15 Ｎ-아실계 아미노산 유도체, 이의 생산방법, 약리학적조성물 및 항알러지제, 소염제 및 저지질혈제 형태에서의용도 Expired - Fee Related KR101402855B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2005118635 2005-06-15
RU2005118635/04A RU2335495C2 (ru) 2005-06-15 2005-06-15 N-ацильные производные аминокислот, их фармацевтически приемлевые соли, фармацевтическая композиция и применение в качестве гиполипидемических средств
PCT/RU2006/000311 WO2006135280A1 (en) 2005-06-15 2006-06-15 N-acylic aminoacid derivatives. method for the production thereof, pharmacological composition and the use in the form of anti-allergic, anti-inflammatory and hypolipidemic agents

Publications (2)

Publication Number Publication Date
KR20080039872A KR20080039872A (ko) 2008-05-07
KR101402855B1 true KR101402855B1 (ko) 2014-06-03

Family

ID=37502176

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087001210A Expired - Fee Related KR101402855B1 (ko) 2005-06-15 2006-06-15 Ｎ-아실계 아미노산 유도체, 이의 생산방법, 약리학적조성물 및 항알러지제, 소염제 및 저지질혈제 형태에서의용도

Country Status (10)

Country Link
US (2) US8940780B2 (enExample)
EP (1) EP1905763B1 (enExample)
JP (2) JP2008543830A (enExample)
KR (1) KR101402855B1 (enExample)
CN (1) CN101243053B (enExample)
CA (1) CA2612324C (enExample)
EA (1) EA013057B1 (enExample)
RU (1) RU2335495C2 (enExample)
UA (1) UA94586C2 (enExample)
WO (1) WO2006135280A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2373934C1 (ru) * 2008-03-19 2009-11-27 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств
EP2351848B1 (en) * 2008-10-29 2018-02-28 Kaneka Corporation Method for producing l-amino acid
WO2010064958A2 (ru) * 2008-12-01 2010-06-10 Закрытое Акционерное Общество "Мастерклон" Ингибиторы протеинкиназы с, обладающие противовоспалительным, противоаллергическим и противоастматическим действием
UA115431C2 (uk) * 2011-10-11 2017-11-10 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Застосування глутарилгістаміну для лікування захворювань дихальних шляхів
CN102757388B (zh) * 2012-07-04 2015-05-20 四川百利药业有限责任公司 一种高纯度英加韦林的制备方法
RU2518314C2 (ru) * 2012-08-30 2014-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Способ и средство активации irf-3 для лечения и профилактики заболеваний, вызываемых (+) phk-содержащими вирусами
CN117965408A (zh) 2013-03-15 2024-05-03 模块遗传学公司 酰基氨基酸的产生
RU2665688C2 (ru) * 2013-04-12 2018-09-04 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Производные бисамидов дикарбоновых кислот, их применение, фармацевтическая композиция на их основе, способы их получения
CN103288741B (zh) * 2013-05-24 2015-09-30 华南农业大学 一种组胺半抗原、人工抗原、抗体及其制备方法与应用
WO2015021064A1 (en) * 2013-08-05 2015-02-12 Mannkind Corporation Insufflation apparatus and methods
RU2628800C2 (ru) * 2014-03-12 2017-08-22 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами
CN104119277B (zh) * 2014-07-16 2016-08-17 华南农业大学 一种直接针对组胺的半抗原、人工抗原、抗体及其制备方法与应用
CN104230833B (zh) * 2014-10-07 2016-01-20 张远强 含腈基的四氮唑乙酸类化合物、其制备方法及用途
US11371066B2 (en) 2015-07-13 2022-06-28 Modular Genetics, Inc. Generation of acyl alcohols
RU2665638C1 (ru) * 2017-05-24 2018-09-03 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Амидное соединение и его применение в качестве средства для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами
CN110031583B (zh) * 2018-12-29 2022-01-18 浙江工业大学 分离测定n-琥珀酰色氨酸对映异构体的液相色谱方法
CA3139470C (en) * 2019-05-24 2024-10-15 Stemdr Inc. A composition enabling the prevention or treatment of asthma, rhinitis, or conjunctivitis, comprising N-acylamine acid as the active ingredient.
EP3977990A4 (en) * 2019-05-24 2023-06-14 Stemdr Inc. COMPOSITION FOR THE PREVENTION OR TREATMENT OF ASTHMA, RHINITIS OR CONJUNCTIVITIS WITH N-ACYL AMINO ACID AS THE ACTIVE INGREDIENT

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1020179A2 (en) * 1997-07-04 2000-07-19 Vladimir Evgenievich Nebolsin Peptide derivatives or pharmaceutically acceptable salts thereof, method for producing the same, use of said derivatives and pharmaceutical composition
WO2003072124A1 (en) * 2002-02-28 2003-09-04 Vladimir Evgenievich Nebolsin Induction method for cell differentiation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993004690A1 (en) 1991-09-09 1993-03-18 Peptide Technology Limited Method for the treatment of the complications and pathology of diabetes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1020179A2 (en) * 1997-07-04 2000-07-19 Vladimir Evgenievich Nebolsin Peptide derivatives or pharmaceutically acceptable salts thereof, method for producing the same, use of said derivatives and pharmaceutical composition
WO2003072124A1 (en) * 2002-02-28 2003-09-04 Vladimir Evgenievich Nebolsin Induction method for cell differentiation

Also Published As

Publication number Publication date
RU2005118635A (ru) 2006-11-20
EP1905763A4 (en) 2008-08-27
CN101243053A (zh) 2008-08-13
JP2008543830A (ja) 2008-12-04
US8940780B2 (en) 2015-01-27
UA94586C2 (ru) 2011-05-25
EP1905763B1 (en) 2019-05-08
EP1905763A1 (en) 2008-04-02
US20080319040A1 (en) 2008-12-25
EA200800054A1 (ru) 2008-06-30
JP5836995B2 (ja) 2015-12-24
WO2006135280A1 (en) 2006-12-21
US8318950B2 (en) 2012-11-27
JP2013151551A (ja) 2013-08-08
CA2612324A1 (en) 2006-12-21
US20100267962A1 (en) 2010-10-21
KR20080039872A (ko) 2008-05-07
CN101243053B (zh) 2012-08-08
CA2612324C (en) 2014-12-30
EA013057B1 (ru) 2010-02-26
RU2335495C2 (ru) 2008-10-10

Similar Documents

Publication Publication Date Title
JP5836995B2 (ja) アミノ酸のｎ−アシル誘導体、その製法、薬理組成物および抗−アレルギー性、抗−炎症性および抗−脂血性薬剤としてのその使用
RU2749213C2 (ru) Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе
KR20130056244A (ko) 시클로알킬카르복스아미도-인돌 화합물의 제조 방법
US6303617B1 (en) Serotonin-like 9-substituted hypoxanthine and methods of use
CN113072484B (zh) 含有琥珀酸酯的磺胺苯甲酰胺类化合物及其制备方法与应用
CA2470037C (en) Prodrugs to d-prolines
JP2025111473A (ja) 左旋性二環式モルホリン及びその塩、その調製方法、医薬組成物、並びに使用
RU2378284C2 (ru) Способы получения n-ацильных производных аминокислот (варианты)
RU2406727C2 (ru) Фармацевтическая композиция, содержащая n-ацильные производные аминокислот, и их применение в качестве противоаллергических, антианафилактических и противовоспалительных средств
EP0321090A2 (en) Isoxazolidine-3,5-diones in the treatment of hyperlipidemia
HK1118816A (en) N-acylic aminoacid derivatives. method for the production thereof, pharmacological composition and the use in the form of anti-allergic, anti-inflammatory and hypolipidemic agents
WO2021009768A1 (en) An oral pharmaceutical composition for alpha- amylase inhibition
JP2002544256A (ja) インドールｓＰＬＡ２インヒビターのモルホリノ−Ｎ−エチルエステル誘導体
CN1934086A (zh) 喹诺酮衍生物胺盐
CN118908913B (zh) 含2,3-二氢噻唑-4-羧酸结构的化合物及其制备方法、用途
CN120500337A (zh) 半乳糖凝集素-3抑制剂及其对阿尔茨海默病的治疗作用
HK1076100B (en) Prodrugs to d-prolines

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20170530

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20190516

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20200528

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20200528

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000